Rhabdomyolysis from simvastatin triggered by infection and muscle exertion

Southern Medical Journal

Volumn 98, Issue 8, 2005, Pages 827-829

  Finsterer, Josef ^a   Zuntner, Georg ^b  

^a NONE   (Austria)

^b NONE

Author keywords

Adverse reaction; Hyperlipidemia; Neuromuscular disorder; Side effect; Statin therapy

Indexed keywords

ALANINE AMINOTRANSFERASE; AMIODARONE; ASPARTATE AMINOTRANSFERASE; AZATHIOPRINE; CLARITHROMYCIN; COLCHICINE; CORTISONE; CREATINE KINASE; CYCLOSPORIN; DANAZOL; DILTIAZEM; FIBRIC ACID DERIVATIVE; FLUCONAZOLE; FUSIDIC ACID; GEMFIBROZIL; INDOMETACIN; ITRACONAZOLE; LACTATE DEHYDROGENASE; NEFAZODONE; NELFINAVIR; RITONAVIR; SIMVASTATIN; TACROLIMUS; TROGLITAZONE; VERAPAMIL;

ADULT; ARTICLE; CASE REPORT; DISEASE ASSOCIATION; DISORDERS OF MITOCHONDRIAL FUNCTIONS; ELECTROMYOGRAPHY; FATIGUE; FEMALE; FEVER; HUMAN; HYPERCHOLESTEROLEMIA; INFECTION; LOW BACK PAIN; MUSCLE EXERCISE; MUSCLE WEAKNESS; MYALGIA; NEUROLOGIC EXAMINATION; PTOSIS; RHABDOMYOLYSIS; SPORT;

ADULT; EXERTION; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; INFECTION; PRECIPITATING FACTORS; RHABDOMYOLYSIS; SIMVASTATIN;

EID: 24144489406     PISSN: 00384348     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.smj.0000170731.44173.34     Document Type: Article

References (17)

1. Finsterer J. Fibrat-/StatinMyopathie. Nervenarzt 2003;74:115-22.
2. Hamilton-Craig I. Statin-associated myopathy. Med J Aust 2001;175:486-489.
3. Andreou ER, Ledger S. Potential drug interaction between simvastatin and danazol causing rhabdomyolysis. Can J Clin Pharmacol 2003;10:172-174.
4. Matzno S, Tazuya-Murayama K, Tanaka H, et al. Evaluation of the synergistic adverse effects of concomitant therapy with statins and fibrates on rhabdomyolysis. J Pharm Pharmacol 2003;55:795-802.
5. Roten L, Schoenenberger RA, Krahenbuhl S, et al. Rhabdomyolysis in association with simvastatin and amiodarone. Ann Pharmacother 2004;38:978-981.
6. Riesco-Eizaguirre G, Arpa-Gutierrez FJ, Gutierrez M, et al. Severe polymyositis with simvastatin use. Rev Neurol 2003;37:934-936.
7. Goli AK, Goli SA, Byrd RP Jr, et al. Simvastatin-induced lactic acidosis: a rare adverse reaction? Clin Pharmacol Ther 2002;72:461-464.
8. Phillips PS, Haas RH, Bannykh S, et al. Statin-associated myopathy with normal creatine kinase levels. Ann Intern Med 2002;137:581-585.
9. Jamil S, Iqbal P. Rhabdomyolysis induced by a single dose of a statin. Heart 2004;90:e3.
10. Matsuyama K, Nakagawa K, Nakai A, et al. Evaluation of myopathy risk for HMG-CoA reductase inhibitors by urethane infusion method. Biol Pharm Bull 2002;25:346-350.
11. Morales D, Chung N, Zhu JR, et al. Efficacy and safety of simvastatin in Asian and non-Asian coronary heart disease patients: a comparison of the GOALLS and STATT studies. Curr Med Res Opin 2004;20:1235-1243.
12. de Lemos JA, Blazing MA, Wiviott SD, et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA 2004;292:1307-1316.
13. Skrabal MZ, Stading JA, Monaghan MS. Rhabdomyolysis associated with simvastatin-nefazodone therapy. South Med J 2003;96:1034-1035.
14. Aboulafia DM, Johnston R. Simvastatin-induced rhabdomyolysis in an HIV-infected patient with coronary artery disease. AIDS Patient Care STDS 2000;14:13-18.
15. Sinzinger H, O'Grady, J. Professional athletes suffering from familial hypercholesterolaemia rarely tolerate statin treatment because of muscular problems. Br J Clin Pharmacol 2004;57:525-528.
16. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-245.
17. Caldwell SH, Hespenheide EE, von Borstel RW. Myositis, microvesicular hepatitis, and progression to cirrhosis from troglitazone added to simvastatin. Dig Dis Sci 2001;46:376-378.